TScan Therapeutics Inc.
TCRX | NASDAQ
$0.37
$0.00 (-0.24%)
Nov 2, 2026, 12:48 PM ET · Market open
Market Data
Market Cap $22.65M
Enterprise Value $13.39M
Beta 1.07
Average Volume 711.67K
Shares Outstanding (Diluted) 129.95M
Shares Change YoY 0.17%
Institutional Ownership 24.99%
Exchange NASDAQ
ISIN US89854M1018
Price Performance
Price Change 1M -51.2%
Price Change 3M -63.6%
Price Change 6M -66.9%
Price Change YTD -63.6%
Price Change 1Y -78.8%
Price Change 3Y -84.6%
Price Change 5Y -95.7%
1M CAGR (ann.) -29.1%
1Y CAGR (ann.) -63.0%
5Y CAGR (ann.) -42.5%
All-Time CAGR -41.6%
Valuation
PE Ratio -0.41
Forward PE N/A
PEG Ratio -0.04
Forward PEG N/A
PS Ratio 3.19
Forward PS 3.50
PB Ratio 0.33
P/FCF Ratio -0.19
P/Adj. FCF Ratio -0.18
P/OCF Ratio -0.42
EV/Sales 1.88
EV/EBIT -0.12
EV/EBITDA -0.12
EV/FCF -0.11
Earnings Yield -245.9%
FCF Yield -522.9%
Adj. FCF Yield -566.3%
Financial Health
Net Cash $67.38M
Total Debt $90.89M
Cash & Short-Term Investments $100.16M
Total Assets $171.45M
Current Ratio 3.37
Quick Ratio 3.37
Debt / Equity Ratio 1.32
Debt / EBITDA -0.81
Debt / FCF -0.77
OCF / Debt -1.28
Interest Coverage -43.22
Altman Z-Score -6.02
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 90.3%
Operating Profit Margin -1695.2%
EBITDA Margin -1575.6%
Net Profit Margin -1655.3%
FCF Margin -1665.6%
Adj. FCF Margin -1804.0%
SBC / Revenue 138.4%
SBC Impact (per share) -8.3%
Returns
Return on Assets -68.7%
Return on Equity -108.7%
Return on Invested Capital -75.4%
Return on Capital Employed -85.8%
Return on Tangible Assets -68.7%
Historical Growth (CAGR)
Revenue CAGR 3Y -8.6%
Revenue CAGR 5Y 56.9%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 21.2%
EPS CAGR 5Y 0.8%
EPS CAGR 10Y N/A
FCF CAGR 3Y -32.5%
FCF CAGR 5Y -364.9%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 8
EPS Growth Next 3Y 6.2%
Revenue Growth Next 3Y 64.9%
Earnings Date Nov 11, 2026
EPS Estimate (next Q) -$0.30
EPS Growth Est (next Q) 7.1%
Revenue Est (next Q) $1.45M
Revenue Growth Est (next Q) -42.3%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $7.50
Price Target Upside 1927.0%
Cash Flow
Operating Cash Flow $-116.28M
Free Cash Flow $-118.44M
Adj. Free Cash Flow $-128.28M
FCF Per Share -$0.91
OCF Per Share -$0.89
OCF/S Ratio -1635.2%
Income Statement
Revenue $7.11M
Gross Profit $6.42M
Operating Income $-120.54M
EBITDA $-112.04M
Net Income $-117.71M
EPS (Diluted) -$0.91
Revenue / Employee $50.08K
Profit / Employee $-828.96K
Employees 142
Add to Watchlist
Select watchlists to add or remove TCRX